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ABSTRACT
Background/Objective The incidence of pain and/or
fatigue in people with psoriatic arthritis (PsA) is associated
with reduced health-related quality of life (HRQoL) and the
ability to work, despite modern advanced therapeutic
approaches. This real-world, international study examined
these relationships in patients with PsA treated with tumour
necrosis factor inhibitors (TNFi).
Methods Data from 13 countries were analysed. Patients
with PsA and their physicians completed questionnaires
capturing demographics, current therapy, current disease
status, HRQoL and work status via Medical Outcomes Study
36-Item Short-Form version 2 (SF-36v2), 3-level
5-dimension EuroQoL questionnaire, Health Assessment
Questionnaire Disability Index, and Work Productivity and
Activity Impairment (WPAI) questionnaire.
Results 640 patients with PsA were included who had
been receiving TNFi for ≥3 months and had completed SF-
36v2 bodily pain and vitality domains. Of these, 33.1%,
29.2% and 37.7% of patients reported no, moderate and
severe pain, respectively, and 31.9%, 22.5% and 45.6% of
patients reported low, moderate and severe fatigue,
respectively. Scores across HRQoL variables and WPAI were
significantly different across pain and fatigue cohorts (all
p<0.0001), with HRQoL and WPAI measures considerably
worse in patients with moderate to severe pain or fatigue
than those with low pain or fatigue.
Conclusions Despite treatment with biologic agents such
as TNFi, data from this global study demonstrated that
substantial pain and/or fatigue persist in patients with PsA
and that these are significantly associated with reduced
HRQoL, physical function and work productivity. These
findings suggest that there is an unmet need for additional
PsA therapies.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic inflamma-
tory disease with diverse effects on both skin
and joints, varied course and long-term
impact on patients’ lives.1–4 The prevalence
of PsA varies geographically, from 0.001%
adults in Japan, 0.16% in the USA, up to
0.42% in Italy, and can occur in up to 40%
of patients with psoriasis.1–4
Patients with PsA experience local and sys-
temic symptoms, erosive joint disease,
impaired functioning and higher mortality.1
2 Pain and fatigue, common symptoms in
patients with PsA, are often severe and repre-
sent an important element in the patient con-
cept of PsA disease activity.5–8 Pain in PsA may
be persistent, and remains present even in
patients who achieve minimal disease activity
and who are on pharmacotherapy.8–10 People
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Key messages
What is already known about this subject?
► Pain and/or fatigue are significant burdens for people
with psoriatic arthritis (PsA).
What does this study add?
► This study is the first global real-world analysis of the
relationship between pain and/or fatigue with health-
related quality of life (HRQoL) and work productivity
in patients with psoriatic arthritis (PsA) treated with
tumour necrosis factor inhibitors (TNFi).
► Our results show that greater severity of pain and/or
fatigue is associated with decreased HRQoL, as well
as reduced physical functioning, ability to participate
in daily activities and work productivity.
► Our study confirms previous reports that patients
with PsA commonly report pain despite being
treated with TNFi.
How might this impact on clinical practice?
► Improved disease management with modern
advanced therapies may address the significant
burden of pain and/or fatigue associated with
reduced HRQoL in people with PsA.
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with PsA report ‘role limitation’ and body pain, which can
cause severe disability and seriously impact quality of
life.11 Severe fatigue has been described as overwhelming
and unlike normal tiredness, permeating every aspect of
life and difficult to self-manage with little outside
support.12 It is difficult to assess how widespread severe
fatigue is among patients with PsA as multiple instru-
ments have been used to assess fatigue in both research
and clinical practice. However, estimates are that 57% of
patients with PsA suffer from severe fatigue.5 There is
a scarcity of information of the impact of fatigue on
health-related quality of life (HRQoL) and ability to
work in this patient population.5 6
It has been shown that the proinflammatory cytokines
tumour necrosis factor alpha (TNFα), interleukin 23 (IL-
23), interleukin 17 (IL-17) and interleukin 6 (IL-6) are
elevated in PsA13–17; therefore, current treatments avail-
able are targeted to these pathways. Therapy for PsA
involves conventional synthetic disease-modifying anti-
rheumatic drugs (DMARDs), targeted synthetic DMARDs
such as apremilast and tofacitinib, and biologic DMARDs
(bDMARDs). TNF inhibitors (TNFi) have historically
been the most widely used bDMARDs.18 19
The purpose of this international study was to evaluate
the frequency and severity of pain and fatigue in patients
with PsA treated with TNFi in a real-world setting and
explore the relationship of pain and fatigue severity with
HRQoL and ability to work.
MATERIAL AND METHODS
Data source
This study was a retrospective analysis using data from the
Adelphi PsA Disease Specific Program (DSP) conducted in
13 countries between 2015 and 2016 in the USA and Mex-
ico (N America), Europe (EU5; covering France, Germany,
Italy, Spain and the UK), Asia-Pacific (APAC; covering
Japan, South Korea, Taiwan and Australia), and Turkey
and Middle East (T&ME; covering Turkey and the United
Arab Emirates).20 DSPs are large, multinational surveys
designed to identify current disease management and
patient- and physician-reported disease impact. They are
point-in-time surveys conducted in real-world clinical
practice.
Physicians included in the survey were instructed to com-
plete a prespecified form for the next one to eight (variable
by country) consecutive patients with active PsA who visited
for diagnosis or routine care. Physician-reported forms
included detailed questions querying patient demo-
graphics, clinical assessments, medication use and treat-
ment history. Completion of the physician-reported form
was undertaken through consultation of existing patient
clinical records, as well as the judgement and diagnostic
skills of the respondent physician, which is entirely consis-
tent with decisions made in routine clinical practice.
Each patient for whom a physician-reported form was
completed was invited to complete a voluntary patient-
reported form, providing informed consent to participate.
Patient-reported forms included the 3-level 5-dimension
EuroQoL questionnaire (EQ-5D-3L),21 Medical Outcomes
Study 36-Item Short-Form health survey version 2 (SF-
36v2),22 and Work Productivity and Activity Impairment
(WPAI) general health questionnaire.23 Patients completed
their forms independently from physicians and returned
them in sealed envelopes to ensure confidentiality.
The DSP collected retrospective data using a non-
interventional market research approach; no identifiable
protected health information was collected. The DSP was
conducted in accordance with the relevant legislation at
the time of data collection, including the US Health
Insurance Portability and Accountability Act 199624 and
Health Information Technology for Economic and Clin-
ical Health Act legislation.25 As this market research was
run in accordance with the European Pharmaceutical
Marketing Research Association guidelines, it did not
require ethics committee approvals.26
Participating physicians and patients
Rheumatologists and dermatologists were eligible to par-
ticipate in the study if they had worked ≥3 years as a phy-
sician, had qualified between 1979 and 2012, and were
responsible for treatment decisions and management of
patients with PsA.
Patients were eligible for inclusion in the study if they
were ≥18 years old with a physician-confirmed diagnosis
of PsA and were not currently enrolled in a clinical trial.
Patients were eligible for inclusion in the analysis if they
were receiving TNFi for ≥3months and completed the SF-
36v2 health survey. There were no exclusion criteria in
the study.
Patient characteristics were provided by physicians, cov-
ering demographics, comorbidities including fibromyal-
gia, disease status including duration of disease, presence
of inflammation, presence of enthesitis and treatment
details including type of immunomodulatory therapy
and use of prescribed and non-prescribed pain medica-
tion. Patient-reported happiness was assessed using SF-
36v2 question 9 ‘How much of the time during the past
week have you been happy?’with possible responses: all of
the time, most of the time, some of the time, a little of the
time, none of the time.
Study variables
The SF-36v2 includes eight domains; bodily pain (BP)
domain scores were stratified into tertiles to define
patient cohorts with low, moderate or severe pain. The
SF-36v2 vitality (VT) domain was used as an inverse con-
struct for fatigue, and scores were stratified into tertiles
to define patient cohorts with high vitality (low fatigue),
moderate vitality (moderate fatigue) and low vitality
(severe fatigue), balancing patient numbers between
the three groups as far as possible while still satisfying
the clinical definitions.27 The EQ-5D-3L questionnaire,
Health Assessment Questionnaire Disability Index
(HAQ-DI), SF-36v2 domains and WPAI questionnaire
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were also used to assess patient outcomes.23 28 SF-36v2
age and gender normative data were generated based on
US norms published in SF-36v2 manuals and updates.27
Statistical analyses
Descriptive analyses were conducted at global and regio-
nal levels (N America, EU5, APAC and T&ME). Catego-
rical variables were described by counts and proportion of
respondents, and continuous numerical variables were
described by their means and SD.
Statistical differences across patient-reported outcomes
by tertiles of pain and fatigue were assessed separately
using Kruskal-Wallis tests for continuous or ordinal data,
and χ2 tests for categorical data. A significance level of
95% was used throughout. All analyses were conducted in
Stata Statistical Software: Release 15 (StataCorp LP, Col-
lege Station, TX).
RESULTS
Patients and physicians
Of 3782 patients with PsA who participated in the study,
1475 (39%) patients had been receiving TNFi for at least
3 months at the time of data collection. Of those, 640
(43.4%) patients (N America, n=176; EU5, n=329; APAC,
n=97; T&ME, n=38) who completed both the SF-36v2 BP
and VT domains were included in this analysis. Patient
demographics and baseline characteristics for all patients
by inclusion status and geographical region can be found
in online supplementary table 1. The included patients
were recruited by 320 physicians from 13 countries (N
America, n=91; EU5, n=164; APAC, n=47; T&ME, n=18).
Of 640 patients included in the analysis, 625 (97.7%)
patients completed the EQ-5D-3L questionnaire and 623
(97.3%) patients completed the WPAI questionnaire, of
whom 458 (84.0%) were employed at the time of ques-
tionnaire completion.
Levels of pain and fatigue
Stratification of patients based on SF-36v2 BP domain
scores resulted in three similarly sized patient tertiles of
low pain (BP score: 76–100; n=212 (33.1%)), moderate
pain (BP score: 53–75; n=187 (29.2%)) and severe pain
(BP score: 0–52; n=241 (37.7%)) (table 1). The SF-36v2 BP
domain scores were correlated with pain dimension of the
EQ-5D-3L (spearman correlation coefficient=0.6756).
Stratification of patients based on SF-36v2 VT domain
scores resulted in three similarly sized patient tertiles of
low fatigue (VT score: 66–100; n=204 (31.9%)), moderate
fatigue (VT score: 51–65; n=144 (22.5%)) and severe fati-
gue (VT score: 0–50; n=292 (45.6%)).
Pain and fatigue levels by geographical region are
shown in figure 1. Globally, 37.7% and 45.6% of patients
reported severe pain and fatigue, respectively. A higher
proportion of patients in EU5 reported severe pain
(39.5%) and severe fatigue (48.9%) than in other regions
except for T&ME, where 71.1% and 65.8% of patients
reported severe pain and fatigue, respectively.
Patient demographics and clinical characteristics by pain and
fatigue levels
Patient characteristics that differed across pain (age, body
mass index, geographical region, body surface area
(BSA) affected by psoriasis) and fatigue (geographical
region, BSA affected by psoriasis, comorbid fibromyalgia)
levels are reported in table 1.
A higher proportion of patients reporting severe pain
and fatigue had their disease rated as ‘severe’ by their
physician than those reporting no or low pain and fatigue
(Pain: 7.9% vs 0.5%, p<0.0001; Fatigue: 5.8% vs 1.0%,
p<0.0001). A higher proportion of patients reporting
severe pain and fatigue had their disease rated as
‘unstable/deteriorating’ by their physician than those
reporting no or low pain and fatigue (Pain: 16.7% vs
4.2%, p<0.0001; Fatigue: 12.0% vs 2.9%, p=0.0016).
A higher proportion of patients reporting severe pain
and fatigue had current flares than those reporting low
or no pain and fatigue (Pain: 6.7% vs 0.9%, p<0.0001;
Fatigue: 4.8% vs 1.5%, p=0.032). However, 83.3% of
patients reporting severe pain and 88.0% of patients
reporting severe fatigue were considered to have
‘stable/improving’ disease by their physician, while
a notable proportion of patients reporting severe pain
(39.8%) and severe fatigue (45.5%) were deemed to be
in remission, indicating a discordance between patient-
reported pain and/or fatigue and physician’s assessment
of disease (table 1).
Patients reporting severe pain and fatigue had erythro-
cyte sedimentation rate levels at 18.3 mm/hour and
17.1 mm/hour, respectively, compared with patients
with low pain and fatigue with levels at 11.2 mm/hour
and 12.0 mm/hour, respectively (p<0.0001 across low,
moderate and severe pain and fatigue groups). Patients
reporting severe pain and fatigue had C reactive protein
levels at 6.4 mg/L and 5.3 mg/L, respectively, compared
with patients with low pain and fatigue with levels at
2.2 mg/L and 3.4 mg/L, respectively (p<0.0001 across
low, moderate and severe pain groups, and p=0.0115
across low, moderate and severe fatigue groups).
HRQoL by pain and fatigue levels
Figure 2 illustrates global SF-36v2 data reported by
patients with low, moderate and severe pain and fatigue
levels. Scores across all SF-36v2 domains (excluding BP,
which is the reference category) were significantly differ-
ent across the three pain cohorts (p<0.0001) (figure 2A).
Similarly, all SF-36v2 domain scores (excluding VT, which
is the reference category) were significantly different
across the three fatigue cohorts (p<0.0001) (figure 2B).
Scores in patients with moderate or severe pain and/or
fatigue were considerably lower than the normative
scores, whereas patients reporting low pain and/or fati-
gue levels had scores that approximated normal values for
most SF-36v2 domains. In relation to mental health, in
addition to the SF-36v2 Mental Health domain being
significantly different across pain and fatigue cohorts,
patient-reported happiness was also significantly different
Psoriatic arthritis
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Table 1 Patient demographics and clinical characteristics by pain and fatigue levels
Pain Fatigue
Characteristics
Overall
(n=640)
Low
(BP score
76–100)
(n=212)
Moderate
(BP score
53–75)
(n=187)
Severe
(BP score
0–52)
(n=241) P value
Low
(VT score
66–100)
(n=204)
Moderate
(VT score
51–65)
(n=144)
Severe
(VT score
0–50)
(n=292) P value
Age, years
Mean (SD) 48.8
(11.6)
46.2 (11.5) 49.0 (10.6) 50.9 (12.0) 0.0002 47.6 (11.6) 48.6 (11.1) 49.7 (11.8) 0.2428
<65, n (%) 573
(89.5)
197 (92.9) 167 (89.3) 209 (86.7) 0.0981 183 (89.7) 131 (91.0) 259 (88.7) 0.7628
Male, n (%) 357
(55.8)
132 (62.3) 102 (54.5) 123 (51.0) 0.0516 118 (57.8) 79 (54.9) 160 (54.8) 0.7725
Mean (SD)
BMI, kg/m2
26.3
(4.6)
25.4 (3.9) 27.0 (4.7) 26.7 (4.9) 0.0003 25.9 (4.6) 26.3 (4.0) 26.6 (4.9) 0.0739
Patient region,
n (%)
<0.0001 <0.0001
N America 176
(27.5)
59 (27.8) 59 (31.6) 58 (24.1) 70 (34.3) 44 (30.6) 62 (21.2)
EU5 329
(51.4)
113 (53.3) 86 (46.0) 130 (53.9) 99 (48.5) 69 (47.9) 161 (55.1)
APAC 97
(15.2)
40 (18.9) 31 (16.6) 26 (10.8) 35 (17.2) 18 (12.5) 44 (15.1)
T&ME 38 (5.9) 0 (0.0) 11 (5.9) 27 (11.2) 0 (0.0) 13 (9.0) 25 (8.6)
Time since
symptom onset
(years)
(n=531) (n=169) (n=157) (n=205) (n=160) (n=121) (n=250)
Mean (SD) 7.9 (7.5) 7.4 (7.0) 8.0 (6.9) 8.3 (8.3) 0.7556 7.5 (6.6) 7.0 (6.9) 8.6 (8.2) 0.1366
Time since
diagnosis
(years)
(n=571) (n=192 (n=163) (n=216) (n=182) (n=125) (m=264)
Mean (SD) 6.3 (6.4) 6.0 (6.3) 6.6 (6.1) 6.3 (6.7) 0.5556 6.5 (6.5) 5.9 (6.2) 6.3 (6.4) 0.3846
Presence of
psoriasis, n (%)
620
(96.9)
205 (96.7) 184 (98.4) 231 (95.9) 0.3189 198 (97.1) 140 (97.2) 282 (96.6) 0.9200
% BSA
psoriasis
(n=498) (n=169) (n=151) (n=178) (n=163) (n=115) (n=220)
Mean (SD) 9.1
(11.2)
6.5 (9.0) 7.4 (9.4) 13.0 (13.4) <0.0001 7.7 (11.7) 7.0 (7.3) 11.3 (12.2) <0.0001
HLA-B27 (n=236) (n=74) (n=69) (n=93) (n=74) (n=55) (n=107)
+ve, n (%) 92
(39.0)
26 (35.1) 31 (44.9) 35 (37.6) 0.4591 26 (35.1) 31 (56.4) 35 (32.7) 0.7117
Comorbid
fibromyalgia*,
n (%)
23 (3.6) 4 (1.9) 5 (2.7) 14 (5.8) 0.0592 2 (1.0) 6 (4.2) 15 (5.1) 0.0458
Number of TNFi
ever received,
n (%)
(n=640) (n=212) (n=187) (n=241) 0.0227 (n=204) (n=144) (n=292) 0.0139
1 533
(83.3)
184 (86.8) 160 (85.6) 189 (78.4) 181 (88.7) 111 (77.1) 241 (82.5)
2 61 (9.5) 22 (10.4) 15 (8.0) 24 (10.0) 13 (6.4) 17 (11.8) 31 (10.6)
3+ 18 (2.8) 1 (0.5) 4 (2.1) 13 (5.3) 2 (1.0) 5 (3.5) 11 (3.8)
Unknown 28 (4.4) 5 (2.4) 8 (4.3) 15 (6.2) 8 (3.9) 11 (7.6) 9 (3.10)
Current
severity*, n (%)
(n=640) (n=212) (n=187) (n=241) <0.0001 (n=204) (n=144) (n=292) <0.0001
Mild 435
(68.0)
180 (84.9) 148 (79.1) 107 (44.4) 168 (82.4) 107 (74.3) 160 (54.8)
Continued
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across pain and fatigue cohorts (both p<0.0001), with
lower levels of happiness reported by patients with either
severe pain or fatigue (table 2).
Regional SF-36v2 domain scores are presented in
online supplementary table 2. The greatest difference
in domain scores across regions was in the physical func-
tioning domain, where scores ranged from 32.1 in
T&ME to 76.8 in APAC. Scores in T&ME were consis-
tently lower than other regions for all domains with the
exception of General Health where the EU5 score was
lower.
As pain and/or fatigue levels increased from low to
moderate to severe, a significantly higher percentage of
patients reported ‘some’ or ‘extreme’ problems with
mobility, self-care, usual activities, pain and anxiety/
depression as measured by the EQ-5D-3L (all p<0.0001)
(figure 3). EQ-5D-3L, EQ-visual analogue scale (VAS) and
HAQ-DI scores were significantly different across pain
and fatigue cohorts (all p<0.0001), with scores lower in
patients reporting severe pain and/or fatigue compared
with those reporting low pain and/or fatigue (table 2).
Regional EQ-5D-3L, EQ-VAS and HAQ-DI scores can be
found in online supplementary table 2.
Societal burden by pain and fatigue levels
Of 545 patients of working age (<65 years) who pro-
vided employment information, 458 (84.0%) patients
were employed, defined as employed, a student or
a homemaker (table 2). Employment status differed
significantly across pain cohorts (p=0.0001), with
lower employment rates (79.1%, 83.2% and 89.9%)
and higher unemployment/retirement due to PsA
(9.7%, 1.2% and 2.1%) in severe, moderate and low
pain cohorts, respectively. Similar results were seen
across fatigue cohorts (p=0.0001), with lower employ-
ment rate (79.7%, 82.9% and 90.9%) and higher
unemployment/retirement due to PsA (8.9%, 2.4%
and 0%) in severe, moderate and low fatigue cohorts,
respectively. HAQ-DI was significantly different across
patients reporting severe, moderate and low pain and
fatigue (both p<0.0001) (table 2).
All WPAI measures were significantly different across
the pain and fatigue severity cohorts (all p<0.0001), indi-
cating that more severe pain and/or fatigue were asso-
ciated with greater work impairment, more work time
missed and greater impairment while working and during
daily activities (table 2). Overall regional results can be
Table 1 Continued
Pain Fatigue
Characteristics
Overall
(n=640)
Low
(BP score
76–100)
(n=212)
Moderate
(BP score
53–75)
(n=187)
Severe
(BP score
0–52)
(n=241) P value
Low
(VT score
66–100)
(n=204)
Moderate
(VT score
51–65)
(n=144)
Severe
(VT score
0–50)
(n=292) P value
Moderate 182
(28.4)
31 (14.6) 36 (19.3) 115 (47.7) 34 (16.7) 33 (22.9) 115 (39.4)
Severe 23 (3.6) 1 (0.5) 3 (1.6) 19 (7.9) 2 (1.0) 4 (2.8) 17 (5.8)
In remission*,
n (%)
349
(54.5)
151 (71.2) 102 (54.5) 96 (39.8) <0.0001 135 (66.2) 81 (56.3) 133 (45.5) <0.0001
Disease status*,
n (%)
(n=639) (n=212) (n=187) (n=240) <0.0001 (n=204) (n=144) (n=291) 0.0016
Stable/
improving
584
(91.4)
203 (95.7) 181 (96.8) 200 (83.3) 198 (92.1) 130 (90.3) 256 (88.0)
Unstable/
deteriorating
55 (8.6) 9 (4.2) 6 (3.2) 40 (16.7) 6 (2.9) 14 (9.7) 35 (12.0)
Current flare
status*, n (%)
(n=639) (n=212) (n=187) (n=240) 0.0001 (n=204) (n=144) (n=291) 0.032
Never flared 373
(58.4)
144 (67.9) 101 (54.0) 128 (53.3) 133 (65.2) 81 (56.3) 159 (54.6)
Flares, not
current
242
(37.9)
66 (31.1) 80 (42.8) 96 (40.0) 68 (33.3) 56 (38.9) 118 (40.5)
Currently flaring 24 (3.8) 2 (0.9) 6 (3.2) 16 (6.7) 3 (1.5) 7 (4.9) 14 (4.8)
ESR, mm/hour (n=270) (n=80) (n=97) (n=93) (n=81) (n=68) (n=121)
Mean (SD) 15.4
(12.2)
11.2 (8.7) 16.2 (13.0) 18.3 (13.0) <0.0001 12.0 (10.3) 16.6 (15.8) 17.1 (10.6) 0.0001
CRP, mg/L (n=264) (n=77) (n=94) (n=93) (n=78) (n=66) (n=120)
Mean (SD) 4.8 (7.2) 2.2 (3.0) 5.3 (7.2) 6.4 (9.1) <0.0001 3.4 (4.7) 5.4 (8.4) 5.3 (7.8) 0.0115
APAC, Asia-Pacific Region; BMI, body mass index; BP, bodily pain domain; BSA, body surface area; CRP, C reactive protein; ESR, erythrocyte
sedimentation rate; EU5, Europe; HLA-B27, human leucocyte antigen B27; N America, the USA andMexico; T&ME, Turkey and theMiddle East;
TNFi, tumour necrosis factor inhibitors; VT, vitality domain.
*Physician reported. Tertiles generated to balance patient numbers between the groups, while still satisfying the definitions of low,moderate and
severe pain and fatigue.
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Figure 2 Spydergram29 of SF-36v2 domain scores by pain (A) and fatigue (B) levels. A/G, age/gender; SF-36v2, Medical
Outcomes Study 36-Item Short-Form version 2. All p<0.0001 across levels of pain and fatigue (low, moderate, severe).
Figure 1 Pain and/or fatigue levels by region. SF-36v2 BP and VT domain scoreswere stratified into tertiles to define patients
with low, moderate or severe pain or fatigue. APAC, Asia-Pacific Region; BP, bodily pain; EU5, Europe; N America, the USA
and Mexico, T&ME, Turkey and the Middle East; VT, vitality.
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found in online supplementary table 2. Regionally, the
majority of patients were employed; among employed
patients who completed the WPAI questionnaire, the
overall work impairment, presenteeism and activity
impairment was around 20–30% in N America, EU5 and
APAC, and approximately 70% of patients in T&ME.
Absenteeism ranged from 0.8% in APAC to 15%
in T&ME.
Table 2 Patient-reported quality of life and societal burden by pain and fatigue levels
Pain Fatigue
Overall
Low
(BP
score
76–100)
Moderate
(BP score
53–75)
Severe
(BP
score
0–52) P value
Low
(VT
score
66–100)
Moderate
(VT score
51–65)
Severe
(VT
score
0–50) P value
EQ-5D-3L (n=625) (n=208) (n=183) (n=234) (n=198) (n=143) (n=284)
Mean (SD) 0.756
(0.288)
0.960
(0.094)
0.790
(0.213)
0.548
(0.313)
<0.0001 0.940
(0.100)
0.776
(0.247)
0.618
(0.320)
<0.0001
EQ-VAS (n=625) (n=206) (n=187) (n=236) (n=201) (n=144) (n=284)
Mean (SD) 69.9
(19.2)
82.0 (15.6) 72.1
(14.4)
57.5
(18.0)
<0.0001 82.5 (13.6) 71.8
(17.3)
60.0
(18.1)
<0.0001
HAQ-DI (n=625) (n=206) (n=184) (n=235) (n=200) (n=141) (n=284)
Mean (SD) 0.6 (0.7) 0.1 (0.3) 0.5
(0.5)
1.2
(0.7)
<0.0001 0.1 (0.3) 0.5
(0.6)
1 (0.8) <0.0001
SF-36v2 Q9. How much time
during the past week . . . have
you been happy?, n (%)
(n=635) (n=211) (n=186) (n=238) <0.0001 (n=203) (n=143) (n=289) <0.0001
All/most of the time 298
(46.9)
152 (72.0) 90
(48.4)
56
(23.5)
180 (88.7) 68
(47.6)
50
(17.3)
Some of the time 220
(34.6)
42 (19.9) 73
(39.2)
105
(44.1)
21 (10.3) 61
(42.7)
138
(47.8)
A little/none of the time 117
(18.4)
17 (8.1) 23
(12.4)
77
(32.4)
2 (1.0) 14 (9.8) 101
(34.9)
Current employment status
among patients of working age,
n (%)
(n=545) (n=188) (n=161) (n=196) <0.0001 (n=176) (n=123) (n=246) 0.0001
Employed/Student/Homemaker 458
(84.0)
169 (89.9) 134
(83.2)
155
(79.1)
160 (90.9) 102
(82.9)
196
(79.7)
Unemployed/retired not due to
condition or unspecified
25 (4.6) 15 (8.0) 25
(15.5)
22
(11.2)
16 (9.1) 18
(14.6)
28
(11.4)
Unemployed/retired due to
condition
62
(11.4)
4 (2.1) 2 (1.2) 19 (9.7) 0 (0.0) 3 (2.4) 22 (8.9)
WPAI: Overall Work
Impairment, %
(n=319) (n=117) (n=98) (n=104) (n=113) (n=73) (n=133)
Mean (SD) 26.9
(25.6)
8.5 (13.5) 25.1
(19.1)
49.4
(24.0)
<0.0001 9.5 (12.0) 28.5
(24.9)
40.9
(25.7)
<0.0001
WPAI: Presenteeism, % (n=337) (n=129) (n=101) (n=107) (n=122) (n=76) (n=139)
Mean (SD) 24.0
(23.4)
7.8 (12.6) 22.0
(16.1)
45.3
(22.8)
<0.0001 8.3 (10.5) 26.6
(23.2)
36.3
(23.8)
<0.0001
WPAI: Absenteeism, % (n=329) (n=117) (n=100) (n=112) (n=114) (n=76) (n=139)
Mean (SD) 7.2
(18.4)
0.5 (2.2) 5.6
(14.6)
15.6
(26.2)
<0.0001 1.9 (10.7) 6.2
(17.4)
12.1
(22.4)
<0.0001
WPAI: Activity Impairment, % (n=623) (n=207) (n=183) (n=233) (n=200) (n=141) (n=282)
Mean (SD) 32.2
(27.4)
8.9 (12.1) 27.4
(17.8)
56.6
(23.0)
<0.0001 10.9 (13.6) 31.3
(23.7)
47.7
(26.1)
<0.0001
Tertiles generated to balance patient numbers between the groups, while still satisfying the definitions of low, moderate and severe pain and
fatigue.
BP, bodily pain domain; EQ-5D-3L, 3-level version of 5-dimension EuroQol questionnaire, EQ-VAS, EuroQol visual analogue scale; HAQ-DI,
Health Assessment Questionnaire Disability Index; SF-36v2, Medical Outcomes Study 36-Item Short-Form version 2; VT, vitality; Q, question;
WPAI, Work Productivity and Activity Impairment questionnaire.
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Use of pain medication by pain levels
Globally, the use of non-prescription pain medication, pre-
scribed non-steroidal anti-inflammatory drugs (NSAIDs)
and opioids was significantly different across pain severity
cohorts (figure 4). Non-prescription pain medication use
was 4.8%, 13.7% and 23.5% (p<0.0001); prescription
NSAID use was 23.1%, 28.9% and 38.6% (p=0.0014); and
opioid use was 0.5%, 1.6% and 4.1% (p=0.0229) in patients
reporting low, moderate and severe pain, respectively.
DISCUSSION
To our knowledge, this is the first global real-world study of
the relationship between pain and/or fatigue withHRQoL
and work status in patients with PsA treated with TNFi. We
observed that higher levels of pain and/or fatigue were
associated with decreased HRQoL, as well as reduced phy-
sical functioning, ability to participate in activities of daily
living and work productivity. Our results also suggest
a discordance between patient-reported pain and/or fati-
gue and physicians’ assessment of disease control.
Our results are in agreement with other studies that
pain is a common complaint in patients with PsA treated
with TNFi therapy.8–10 Patients reporting severe pain also
exhibited more severe psoriasis. As pain is a common
symptom of psoriasis,30 it may be that the skin-
component of PsA, for example, itching, is a contributor
to the pain these patients experience. In our study, we
observed statistically increased levels of inflammatory
markers with greater severity of pain; though these abso-
lute levels were not high, they may indicate that the dis-
ease is not under control with the ongoing treatment. We
previously reported that even while experiencing a lack of
efficacy, switching of TNFi was often delayed in patients
with PsA.31 In addition, we observed a higher rate of
physician-reported fibromyalgia in patients reporting
severe pain and/or severe fatigue, which is consistent
with previous reports that patients with PsA often exhibit
widespread pain from fibromyalgia and that severe fati-
gue is common in patients with PsA with co-morbid
fibromyalgia.5 32 The prevalence of moderate to severe
fatigue in our study (63%) is in line with a previous esti-
mate of fatigue of 57% in this patient population.5
Our study demonstrates that patients reporting severe
pain and/or fatigue have reduced HRQoL, impaired
ability to work and high rates of unemployment and
retirement compared with patients reporting low pain
and/or low fatigue. This finding is consistent with
a report that overall employment rates are significantly
lower in patients with rheumatic diseases than in the
general population, especially in those with ankylosing
spondylitis and PsA.33–35 Unemployment and work
impairment, including time away from work (absentee-
ism) or reduced effectiveness at work (presenteeism),
affects up to 50%of people with PsA.6 ANational Psoriasis
Foundation (US) survey found that 49% of respondents
routinely missed work due to psoriasis or PsA, with more
than 10 workdays per month missed by 31% of those
respondents.36 Impaired ability to work impacts HRQoL
and is costly to society as a whole.37 38 In the Norwegian
(NOR-DMARD) study, the cost of absenteeism in patients
with PsA taking bDMARDs over a 2-year period was
€111 200.38
A recent study comparing the perceptions of psoriatic
disease symptoms in the USA revealed areas of discor-
dance between both patients and physicians, and between
rheumatologists and dermatologists, on a comprehensive
set of disease symptoms and functional impacts.39 In agree-
ment with this and other studies, we also observed discor-
dance between patient-reported symptoms and physician’s
assessment of disease in our global patient sample.39–41
A major strength of this study is that it presents real-
world data in patients with PsA treated with TNFi around
the world, and the negative impact on patient’s HRQoL
Figure 3 EQ-5D-3L by pain and/or fatigue levels. Categories of EQ-5D-3L responses are percentages of patients with (a) no
problems, (b) some problems and (c) confined to bed/unable to perform task/extreme problems; only (b) and (c) are shown
on the graph. P values across (a), (b) and (c) response categories of EQ-5D-3L for each level of pain and fatigue (low,
moderate and severe) are all p<0.0001.
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and WPAI associated with pain and/or fatigue despite
advanced therapy. However, several potential limitations
associated with data derived from this study should be
considered. It has been suggested that domains within
patient-reported outcome measures are correlated with
each other; therefore, analysis between domains within
the same outcome measure should be interpreted with
caution. Cross-sectional studies are limited in their selec-
tionof patients, sample size anddata collection. In contrast
to a clinical trial where disease activity is assessed by a range
of validatedmeasures, physicians’ ratings of disease activity
may be considered subjective. However, our study reflects
physician practice in a real-world clinical setting where
assessments may include a global assessment rather than
focusing on disease activity. Another limitation of this
study is that it is not possible to determine the impact of
undiagnosed fibromyalgia on our results despite observing
that overall physician-reported comorbid fibromyalgia
levels were low yet increased in the patient groups with
high pain and/or fatigue. Also, there is likely variability in
clinician and regional sensitivity to, and reporting of, fibro-
myalgia. Another limitation of our study is that we did not
compare pain and/or fatigue in patients with PsA not on
TNFi with those on TNFi. While we do show that there is
still a major unmet need (continuing pain and/or fatigue)
in patients treated with TNFi, there is a possibility that for
patients not treated this need is even higher. We did not
capture patient-reported details on depression, which is
associated with the incidence and severity of disease activity
and HRQoL. For the purposes of the analysis, working age
was set to patients ≤65 years, meaning that the variable
working age by country was not considered. In general,
regional results were consistent with global results, with the
exception of T&ME, where most outcome measures were
worse than those observed in other regions; however, since
therewas a low sample size in this region (n=38), results for
T&ME should be interpreted with caution. Finally,
although recall bias is a common limitation of surveys,
data in our study were collected at the time of patients’
appointments, thus reducing the likelihood of recall bias.
CONCLUSIONS
Our study is the first global real-world analysis of the
relationship between pain and/or fatigue with
HRQoL and WPAI in patients with PsA treated with
TNFi. Our results show that greater severity of pain
and/or fatigue are associated with decreased
HRQoL, as well as reduced physical functioning, abil-
ity to participate in daily activities and work produc-
tivity. Our study confirms previous reports that
patients with PsA commonly report pain despite
being treated with TNFi.8 The high burden that
severe pain and/or fatigue, in spite of TNFi treat-
ment, place on patients in terms of limited function,
diminished HRQoL and reduced ability to contribute
to society as part of the workforce indicate that these
are areas of significant unmet need in the treatment
and management of PsA.
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